Second line use of a sulfonylurea in type 2 diabetes treatment is associated with an increased the risk of cardiovascular and hypoglycaemic events, an observational study of UK data has found. Published in the BMJ, the analysis of outcomes in more than 77,000 patients taking metformin suggests that increases in myocardial infarction and hypoglycaemic events are ...
Second line sulfonylurea use linked to cardiovascular risk in T2D
By Michael Woodhead
26 Jul 2018